NFA
MYOV

Nationwide Fund Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

Nationwide Fund Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,722
Closed -$44K – 3288
2017
Q1 		$44K Buy
+3,722
New +$42.7K ﹤0.01% 3004

Other funds holding MYOV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Nationwide Fund Advisors's MYOV Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q2 2017, closing a stake of 3,722 shares — an estimated $44K sold.

Nationwide Fund Advisors first reported a position in MYOV in Q1 2017 and held it in 1 quarter. The position peaked at $44K in Q1 2017. 42 funds tracked by Wall St. Rank hold MYOV as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Myovant Sciences Ltd. position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 3,722 Myovant Sciences Ltd. shares in Q2 2017, an estimated $44K.
  • Nationwide Fund Advisors first reported a position in Myovant Sciences Ltd. in Q1 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's Myovant Sciences Ltd. position peaked at $44K in Q1 2017.
  • 42 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.